提高疫苗接种率的受种者导向干预随机试验经济数据综合
该综述系统检索随机对照试验中的经济数据,评估高收入及中高收入国家提高疫苗接种率的受种者导向干预。共筛选2803篇报告,37项研究符合标准,其中16项完整经济学评价、10项成本分析、10项报告财政激励金额。经济数据多针对流感(n=15)和人乳头瘤病毒(n=11)疫苗,干预以提醒类为主(n=13)。结论指出缺乏成本数据和完整经济学评价。
要点
- 37项研究中仅16项为完整经济学评价,10项为成本分析。
- 经济数据最常报告于流感(n=15)和HPV(n=11)疫苗干预。
- 提醒类干预研究最多(n=13),成本构成差异大。
核心结论
- 综述强调提高疫苗接种率干预试验缺乏成本数据和完整经济学评价。
- 以一致方式收集和报告相关经济数据对知情决策至关重要。
研究设计与样本
- 对经济学证据的综述,并行对提高疫苗接种率干预有效性的随机对照试验进行系统综述。
- 纳入报告随机对照试验相关经济数据(含经济学评价或成本分析)的研究,检索截至2024年4月,另针对性检索MEDLINE至2024年3月及NHS经济评价数据库存档。
- 使用Drummond清单评估经济学评价质量,数据采用叙述性综合。
主要发现
- 共筛选2803篇报告,37项研究符合纳入标准。
- 16项研究进行完整经济学评价,10项进行成本分析,其余10项报告财政激励金额。
- 所有成本分析均估算干预实施的直接成本,成本构成差异大。
- 经济数据最常报告于流感疫苗(n=15)和人乳头瘤病毒疫苗(n=11)干预。
- 纳入研究多数为提醒类干预(n=13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 综述强调提高疫苗接种率干预试验缺乏成本数据和完整经济学评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Achieving high vaccine uptake is key to maximizing the effectiveness of immunization programmes. Decisions around which interventions to implement to increase vaccine uptake need to be informed by both intervention effectiveness and the economic data. We aimed to collate cost analyses and economic evaluations of recipient-focused interventions to increase vaccine uptake for high and upper-middle income countries. METHODS: We conducted a review of the economic evidence, alongside a systematic review of randomized controlled trials (RCTs) on the effectiveness of interventions to increase vaccine uptake. Eligible studies were those reporting economic data (including economic evaluations or cost analyses) pertaining to RCTs included in the systematic review. These studies were identified in two ways: firstly, through the comprehensive systematic review searches (up to April 2024), and secondly, through a targeted search for economic information conducted on MEDLINE to March 2024 and the archived NHS Economic Evaluation Database (EED). The quality of economic evaluations was assessed using the Drummond checklist. Data were narratively synthesized. RESULTS: We screened 2803 reports in total, of which 37 studies met our eligibility criteria. Sixteen conducted full economic evaluations and ten conducted cost analyses, while the remaining ten reported the value of financial incentives that contribute to intervention costs. All cost analyses estimated direct costs related to the implementation of interventions, with substantial variation in terms of cost components. Economic data were most commonly reported for interventions to increase uptake of influenza (n = 15) and human papillomavirus (n = 11) vaccines. Of the included studies, most related to reminder interventions (n = 13). CONCLUSION: Our review highlights a lack of both cost data and full economic evaluations for trials of interventions to increase vaccine uptake. Collecting and reporting relevant economic data in a consistent way is vital for enabling informed decision-making around which interventions to implement.
引用
- Hamashima Y, Breheny K, Davies SR, et al. A synthesis of economic data from randomized trials of recipient-focused interventions to increase vaccine uptake. Vaccine. 2025. PMID: 41192046. doi:10.1016/j.vaccine.2025.127906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。